Skip to main content

C4 Therapeutics, Inc. (CCCC)

NASDAQ: CCCC · Delayed Price · USD
50.37
-0.13 (-0.26%)
After-hours:Sep 23, 2021 4:06 PM EDT
50.50
0.45 (0.90%)
At close: Sep 23, 4:00 PM
Market Cap2.43B
Revenue (ttm)33.92M
Net Income (ttm)-87.18M
Shares Out48.45M
EPS (ttm)-2.54
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume218,535
Open50.34
Previous Close50.05
Day's Range49.55 - 51.21
52-Week Range22.40 - 51.21
Betan/a
AnalystsStrong Buy
Price Target61.33 (+21.4%)
Est. Earnings DateNov 10, 2021

About CCCC

C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for syn...

IndustryBiotechnology
IPO DateOct 2, 2020
Employees99
Stock ExchangeNASDAQ
Ticker SymbolCCCC
Full Company Profile

Financial Performance

In 2020, CCCC's revenue was $33.20 million, an increase of 55.25% compared to the previous year's $21.38 million. Losses were -$66.34 million, 94.5% more than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for CCCC stock is "Strong Buy." The 12-month stock price forecast is 61.33, which is an increase of 21.45% from the latest price.

Price Target
$61.33
(21.45% upside)
Analyst Consensus: Strong Buy

News

C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag

The FDA has granted Orphan Drug Designation to C4 Therapeutics Inc (NASDAQ: CCCC) CFT7455 for multiple myeloma. CFT7455 is an orally bioavailable MonoDAC degrader targeting IKZF1/3.

1 month ago - Benzinga

C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

– Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 –

1 month ago - GlobeNewsWire

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma

WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...

1 month ago - GlobeNewsWire

C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Add...

WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...

3 months ago - GlobeNewsWire

C4 Therapeutics Announces Pricing of Public Offering

WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...

3 months ago - GlobeNewsWire

C4 Therapeutics Launches Proposed Public Offering

WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...

3 months ago - GlobeNewsWire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable ...

– CFT7455 is Company's First Program to Advance to Clinic – – CFT7455 is Company's First Program to Advance to Clinic –

3 months ago - GlobeNewsWire

C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on T...

– CFT8919 Induces Tumor Regression in Pre-clinical Models Resistant to First- and Third-generation EGFR Inhibitors –

3 months ago - GlobeNewsWire

C4 Therapeutics Appoints Lauren White as Chief Financial Officer

WATERTOWN, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy dis...

4 months ago - GlobeNewsWire

C4 Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

– Preclinical Data for CFT7455, a novel IKZF1/3 Degrader, in Non-Hodgkin's Lymphoma Xenograft Models Accepted for Presentation at the International Conference on Malignant Lymphoma (ICML)  in June –

4 months ago - GlobeNewsWire

C4 Therapeutics to Present at Upcoming Investor Conferences

WATERTOWN, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy dis...

4 months ago - GlobeNewsWire

C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malig...

– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models –

5 months ago - GlobeNewsWire

C4 Therapeutics Reports Recent Business Highlights and Full Year 2020 Financial Results

– Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On Track for 1H 2021 Initiation Following FDA Clearance of Investigatio...

6 months ago - GlobeNewsWire

C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZ...

WATERTOWN, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy d...

6 months ago - GlobeNewsWire

C4 Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy di...

6 months ago - GlobeNewsWire

C4 Therapeutics to Participate in BMO BioPharma Spotlight Series

WATERTOWN, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy di...

7 months ago - GlobeNewsWire

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable M...

– Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 – – Phase 1/2 Clinical Study of CFT7455 Expected to Initiate in 1H 2021 –

8 months ago - GlobeNewsWire

C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy di...

8 months ago - GlobeNewsWire

ISR Stock: Why Little-Known Isoray Is Surging 200% Today

An FDA nod on Isoray's prostate treatment using brachytherapy seeds sent ISR stock skyrocketing. There's risk with uncertain reward in this biopharma stock.

8 months ago - InvestorPlace

C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year...

– Investigational New Drug (IND) Application for Lead Candidate CFT7455, a MonoDAC™ targeting IKZF1/3 for the Treatment of Hematologic Malignancies, Under FDA Review; Initiation of Phase 1/2 Trial Expec...

8 months ago - GlobeNewsWire

C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach

C4 Therapeutics, along with a host of others, is developing therapeutics in the cutting edge field of protein degraders. Blockbuster drugs like Revlimid and Pomalyst are now known to be protein degraders.

8 months ago - Seeking Alpha

C4 Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

WATERTOWN, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disea...

9 months ago - GlobeNewsWire